Published in
Elsevier, European Journal of Cancer, 17(50), p. 2897-2904, 2014
DOI: 10.1016/j.ejca.2014.07.017
Links
Tools
Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours
Journal article published in 2014 by
Jeffrey R. Infante,
Glen J. Weiss,
Suzanne Jones,
Raoul Tibes,
Todd M. Bauer 
,
Johanna C. Bendell,
James M. Hinson,
Daniel D. Von Hoff,
Howard A. Burris,
Everardus O. Orlemans,
Ramesh K. Ramanathan
,
Johanna C. Bendell,
James M. Hinson,
Daniel D. Von Hoff,
Howard A. Burris,
Everardus O. Orlemans,
Ramesh K. Ramanathan
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 